JNJ
Johnson & Johnson
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Johnson & Johnson reports new TREMFYA (guselkumab) data showing sustained three-year outcomes in moderate-to-severe Crohn's disease and additional evidence in perianal fistulasOct 19, 2026
- CHMP recommends TALVEY (talquetamab) plus daratumumab for earlier-line treatment of relapsed or refractory multiple myelomaOct 16, 2026
- Johnson & Johnson reports TREMFYA as the first and only IL-23 inhibitor to significantly improve spinal pain and stiffness in a landmark axial psoriatic arthritis studySep 25, 2026
- A new model-based analysis further supports the potential of TECVAYLI plus DARZALEX FASPRO to improve long-term survival in earlier-line relapsed or refractory multiple myelomaSep 23, 2026
- CAPLYTA (lumateperone) delivers significant and rapid improvement in bipolar mania in a pivotal Phase 3 trialSep 21, 2026